You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,835,487

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,835,487

Title:	Method of treating multiple sclerosis
Abstract:	The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequalae after multiple sclerosis attacks by administering biotin.
Inventor(s):	Sedel; Frederic (Paris, FR)
Assignee:	Assistance Publique Hopitaux De Paris (Paris, FR)
Application Number:	13/644,615
Patent Claims:	1. A method of treating a patient suffering from multiple sclerosis, comprising administering a therapeutically effective amount of at least 100 mg/day of biotin to a patient in need thereof, wherein said multiple sclerosis is a progressive form of multiple sclerosis. 2. A method for treating sequelae of multiple sclerosis attacks in a patient in need thereof, comprising administering a therapeutically effective amount of at least 100 mg/day of biotin to said patient. 3. The method of claim 1, wherein the daily amount of biotin administered to said patient is between 100 and 500 mg. 4. The method of claim 1, wherein the amount of biotin administered to said patient is at least 300 mg. 5. The method of claim 1, wherein said biotin is in a form suitable for oral administration. 6. The method of claim 1, wherein said biotin is in the form of a composition containing biotin and excipients, without any other active ingredient. 7. The method of claim 1, wherein said biotin is in the form of an injectable composition. 8. The method of claim 2, wherein the amount of biotin administered to said patient is between 100 and 500 mg. 9. The method of claim 2, wherein the amount of biotin administered to said patient is at least 300 mg. 10. The method of claim 2, wherein said biotin is in a form suitable for oral administration. 11. The method of claim 2, wherein said biotin is in the form of a composition containing biotin and excipients, without any other active ingredient. 12. The method of claim 2, wherein said biotin is in the form of an injectable composition. 13. The method of claim 1, wherein treatment with biotin has a duration of at least 3 months. 14. The method of claim 2, wherein treatment with biotin has a duration of at least 3 months. 15. The method of claim 1, wherein the amount of biotin administered to said patient is between 300 and 500 mg, and treatment with biotin has a duration of at least 3 months. 16. The method of claim 2, wherein the amount of biotin administered to said patient is between 300 and 500 mg, and treatment with biotin has a duration of at least 3 months. 17. The method of claim 1, wherein the biotin is administered with one or more of interferon beta, glatiramer acetate, Natalizumab, Gilenya, Fampyra and mitoxantrone. 18. The method of claim 2, wherein the biotin is administered with one or more of interferon beta, glatiramer acetate, Natalizumab, Gilenya, Fampyra and mitoxantrone.

Details for Patent 8,835,487

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004	⤷ Try a Trial	2032-07-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.